Invivyd Inc (IVVD)
$1.32
+0.03
(+2.33%)▲
Performance
- $1.25$1.33$1.32
5.3%
Downside
Day's Volatility :6.02%
Upside
0.75%
- $1.05$5.20$1.32
20.45%
Downside
52 Weeks Volatility :79.81%
Upside
74.62%
Returns
| Period | Invivyd Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -40.0% | 0.0% |
6 Months | -71.4% | 0.0% |
1 Year | -10.42% | 0.0% |
3 Years | -93.82% | -20.2% |
Highlights
Market Capitalization | 159.9M |
Book Value | $1.5 |
Earnings Per Share (EPS) | -1.87 |
Wall Street Target Price | 9.22 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -47.62% |
Return On Equity TTM | -81.87% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -215.1M |
Diluted Eps TTM | -1.87 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.93 |
EPS Estimate Next Year | -0.16 |
EPS Estimate Current Quarter | -0.47 |
EPS Estimate Next Quarter | -0.34 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 598.48%
Technicals Summary
Sell
Neutral
Buy
Invivyd Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Invivyd Inc | 6.61% | -71.4% | -10.42% | -93.82% | -93.82% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Invivyd Inc | NA | NA | NA | -0.93 | -0.82 | -0.48 | NA | 1.5 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Invivyd Inc | Buy | $159.9M | -93.82% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Invivyd Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 72.0%
Institutional Holdings
Maverick Capital Ltd
9.86%Deep Track Capital, LP
9.18%M28 Capital Management LP
7.75%FMR Inc
7.05%Alphabet Inc
3.79%Slate Path Capital LP
3.13%
Company Information
adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.
Organization | Invivyd Inc |
Employees | 94 |
CEO | Mr. David Hering M.B.A. |
Industry | Healthcare |
